Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06620523 · ClinicalTrials.gov registry record · Phase 2
Prevent Cardiac Surgery Associated AKI Trial
A Phase 2 study of Coronary Artery Disease and Surgery, sponsored by George Washington University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
- 1
- Study location
NCT06620523 is a Phase 2 study of Coronary Artery Disease and Surgery that is actively recruiting participants, run by George Washington University. The registered enrollment target is 242 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06620523, a Phase 2 study of Coronary Artery Disease and Surgery, is actively recruiting participants, sponsored by George Washington University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
- 1
- Study location
Study Summary
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Conditions Studied
Interventions
- DRUG CoQ10 1200 mg orally with Glutathione 1000 mg orally
- DRUG Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Study Locations (1)
District of Columbia
- George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2028-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06620523
The ClinicalTrials.gov registry entry for NCT06620523 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which CoQ10 1200 mg orally with Glutathione 1000 mg orally is the first listed.
NCT06620523 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06620523 about?
NCT06620523 is a clinical study titled "Prevent Cardiac Surgery Associated AKI Trial". Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the f...
What is the current status of trial NCT06620523?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2024-07-18. Estimated completion is 2028-06-17.
What conditions does trial NCT06620523 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Surgery, Renal Failure, Surgery--Complications.
What interventions are being tested in trial NCT06620523?
The interventions under investigation include: CoQ10 1200 mg orally with Glutathione 1000 mg orally (DRUG), Group B: Placebo CoQ10 orally and Placebo Glutathione orally (DRUG).
Who is sponsoring clinical trial NCT06620523?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06620523 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
COMPLETED · Phase 2
-
MARS - Monitored Atherosclerosis Regression Study
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.